Effect of simvastatin treatment on bone mineral density and bone turnover in hypercholesterolemic postmenopausal women: a 1-year longitudinal study

Montagnani, A; Gonnelli, Stefano; Cepollaro, C.; Pacini, Sonia; Campagna, Maria Stella; Franci, Maria Beatrice; Lucani, Barbara; Gennari, C

doi:10.1016/s8756-3282(03)00034-6

Cited by 112 publications

(64 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the number of patients in our study is limited, the findings of no significant changes of the serum OC or u -DPD in the fluvastatin -treated group as compared with that in the control group during the study period could suggest an imbalance between bone formation and resorption. These variations of the BMD have been reported to occur to lesser extent with simvastatin treatment in postmenopausal women 45) , as compared to those reported for the majority of antiresorptive drugs 46,47) . However, other drugs used for the treatment of osteoporosis, such as raloxifene 48) and calcitonin 49) , have been reported to markedly reduce the risk of vertebral fractures in the face of a modest increase of the BMD, comparable to that observed with fluvastatin in the present study.…”

Section: Discussionmentioning

confidence: 61%

Fluvastatin Increases Bone Mineral Density in Postmenopausal Women

Gotoh

Mizuno

Ōno

et al. 2011

FJMS

View full text Add to dashboard Cite

:Although several studies have reported a lower risk of osteoporotic fracture in hypercholesterolemic patients (WHO IIa) treated with statin, longitudinal studies on the effects of statins on bone are lacking. The aim of the present study was to evaluate bone mineral density (BMD) and bone turnover changes induced by 3 -year fluvastatin treatment in postmenopausal women. Twenty -eight consecutive postmenopausal non -diabetic, normotensive hypercholesterolemic women (64.0±3.6 years) were treated for 36 months with 30 mg/day fluvastatin and 28 non -diabetic, normotensive normocholesterolemic age -and body mass index -matched postmenopausal women served as the control subjects. The result revealed a significant increase of the BMD as compared with the level at the base line (p<0.001) in the fluvastairn -treated group, from 6 months on ward after the start treatment. Significant differences of the BMD were found between the controls and fluvastatin -treated group (p<0.001) were at 6, 12, 24 and 36 months after the start of the study. In conclusion our results, although obtained small sample of postmenopausal hypercholesterolemic women, suggest a probable favorable effect of fluvastatin on bone formation and BMD.

show abstract

Section: Discussionmentioning

confidence: 61%

Fluvastatin Increases Bone Mineral Density in Postmenopausal Women

Gotoh

Mizuno

Ōno

et al. 2011

FJMS

View full text Add to dashboard Cite

show abstract

“…Ayukawa et al (2009) confirmed that topical application of statins to alveolar bone increased bone formation and concurrently suppressed osteoclast activity at the bone-healing site. In addition, clinical studies reported that statin use is associated with increased bone mineral density (Edwards et al, 2000, Montagnani et al, 2003. Du et al (2009) investigated the effect of simvastatin by oral administration on implant osseointegration in osteoporotic rats and found that it significantly improved bone integration with the implant.…”

Section: Simvastatinmentioning

confidence: 99%

Dental Implant Surface Enhancement and Osseointegration

Anil¹,

Anand²,

Alghamdi³

et al. 2011

Implant Dentistry - A Rapidly Evolving Practice

View full text Add to dashboard Cite

“…Evidence regarding the effects of statins on BMD [50,51] and fracture risk are not completely consistent but do suggest the anabolic potential of these drugs. In fact, a meta-analysis conclude that statins reduce hip fracture risk and, to a lesser extent, nonspine fracture risk [52] .…”

Section: Statinsmentioning

confidence: 97%

Bone anabolics in osteoporosis: Actuality and perspectives

Montagnani¹

2014

WJO

View full text Add to dashboard Cite

Vertebral and nonvertebral fractures prevention is the main goal for osteoporosis therapy by inhibiting bone resorption and/or stimulating bone formation. Antiresorptive drugs decrease the activation frequency, thereby determining a secondary decrease in bone formation rate and a low bone turnover. Bisphosphonates are today's mainstay among antiresorptive treatment of osteoporosis. Also, oral selective estrogen receptor modulators and recently denosumab have a negative effect on bone turnover. Agents active on bone formation are considered a better perspective in the treatment of severe osteoporosis. Recombinant-human parathyroid hormone (PTH) has showed to increase bone formation and significantly decrease vertebral fractures in severe patients, but with a modest effect on nonvertebral fractures. The study of Wnt signaling pathway, that induces prevalently an osteoblastic activity, opens large possibilities to antagonists of Wnt-inhibitors, such as sclerostin antibodies and dickkopf-1 antagonists, with potential effects not only on trabecular bone but also on cortical bone.

show abstract

Effect of simvastatin treatment on bone mineral density and bone turnover in hypercholesterolemic postmenopausal women: a 1-year longitudinal study

Cited by 112 publications

References 27 publications

Fluvastatin Increases Bone Mineral Density in Postmenopausal Women

Fluvastatin Increases Bone Mineral Density in Postmenopausal Women

Dental Implant Surface Enhancement and Osseointegration

Bone anabolics in osteoporosis: Actuality and perspectives

Contact Info

Product

Resources

About